PMC:7321036 / 45844-46120 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T367","span":{"begin":12,"end":17},"obj":"Body_part"},{"id":"T368","span":{"begin":176,"end":184},"obj":"Body_part"},{"id":"T369","span":{"begin":216,"end":220},"obj":"Body_part"}],"attributes":[{"id":"A367","pred":"fma_id","subj":"T367","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A368","pred":"fma_id","subj":"T368","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A369","pred":"fma_id","subj":"T369","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T226","span":{"begin":82,"end":90},"obj":"Disease"},{"id":"T227","span":{"begin":93,"end":102},"obj":"Disease"}],"attributes":[{"id":"A226","pred":"mondo_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A227","pred":"mondo_id","subj":"T227","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T558","span":{"begin":1,"end":2},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T559","span":{"begin":4,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0051719"},{"id":"T560","span":{"begin":107,"end":109},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T561","span":{"begin":173,"end":175},"obj":"http://purl.obolibrary.org/obo/CLO_0008192"},{"id":"T562","span":{"begin":216,"end":220},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T315","span":{"begin":35,"end":45},"obj":"Chemical"},{"id":"T316","span":{"begin":152,"end":156},"obj":"Chemical"},{"id":"T317","span":{"begin":173,"end":175},"obj":"Chemical"},{"id":"T320","span":{"begin":273,"end":275},"obj":"Chemical"}],"attributes":[{"id":"A315","pred":"chebi_id","subj":"T315","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A316","pred":"chebi_id","subj":"T316","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A317","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_50803"},{"id":"A318","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_53793"},{"id":"A319","pred":"chebi_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/CHEBI_73425"},{"id":"A320","pred":"chebi_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}

{"project":"LitCovid-PubTator","denotations":[{"id":"935","span":{"begin":35,"end":45},"obj":"Chemical"},{"id":"936","span":{"begin":82,"end":102},"obj":"Disease"},{"id":"937","span":{"begin":9,"end":11},"obj":"CellLine"}],"attributes":[{"id":"A935","pred":"tao:has_database_id","subj":"935","obj":"MESH:C000606551"},{"id":"A936","pred":"tao:has_database_id","subj":"936","obj":"MESH:C000657245"},{"id":"A937","pred":"tao:has_database_id","subj":"937","obj":"CVCL:4582"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}

{"project":"LitCovid-sentences","denotations":[{"id":"T303","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T304","span":{"begin":113,"end":251},"obj":"Sentence"},{"id":"T305","span":{"begin":252,"end":276},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"(B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h. Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted. Error bars represent SD."}